Search
RO7284755
go.drugbank.com/drugs/DB17527InvestigationalRO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And … /or Metastatic Solid Tumors).
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. … Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Treamid
go.drugbank.com/drugs/DB16365InvestigationalTreamid, also known as bisamide derivative of dicarboxylic acid (BDDA), is a complexing agent that has been found to chelate metal ions, including calcium, copper, iron, magnesium, and zinc. … and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.
Synonyms: Bisamide derivative of dicarboxylic acidNeisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15682ApprovedInvestigationalFS-1502
go.drugbank.com/drugs/DB19287InvestigationalFS-1502 is an antibody-drug conjugate consisting of an anti-HER2 antibody, linker, and Monomethylauristatin F.
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.
Lubazodone
go.drugbank.com/drugs/DB09196ExperimentalIt acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist. … Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was
PI-0824
go.drugbank.com/drugs/DB05516InvestigationalPeptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. … Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies.